JAK medicine for active ulcerative colitis
Part of Digestive system clinical trials.
This study tests whether a JAK-inhibitor medicine can improve symptoms in people with active ulcerative colitis. If you’re currently flaring, it may help calm inflammation and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (age requirement applies) and able to join the study visits
- You have ulcerative colitis that is currently active (a flare or worsening symptoms)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
This study tests a new combination of two drugs to see if they are safe and help reduce ulcerative colitis symptoms. It is for people who have not gotten enough relief from other treatments.
This study tests several new treatments to see if they are safe and helpful for people with moderate to severe ulcerative colitis. If you have not responded well to standard treatments, this might be an option.
This trial tests if reducing the dose of a JAK inhibitor can keep your inflammatory arthritis under control. If you have rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis and are in a stable remission, you may be able to take a lower dose.
This trial tests a combination of two medications—guselkumab and a JAK inhibitor—for people with inflammatory bowel disease that hasn't responded to other treatments. The goal is to see if this combination is safe and effective for patients with hard-to-control Crohn's disease or ulcerative colitis.
Hear when a new Colitis, Ulcerative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.